(Q44644589)

5 December 2017

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors (English)

1 reference

https://api.crossref.org/works/10.1002/CNCR.11775

5 December 2017

0 references

1 reference

29 March 2024

author name string

Thomas Vogt

1

1 reference

5 December 2017

Christian Hafner

2

1 reference

5 December 2017

Klaus Bross

3

1 reference

5 December 2017

Frauke Bataille

4

1 reference

5 December 2017

Karl-Walter Jauch

5

1 reference

5 December 2017

Anna Berand

6

1 reference

5 December 2017

Michael Landthaler

7

1 reference

5 December 2017

Reinhard Andreesen

8

1 reference

5 December 2017

Albrecht Reichle

9

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

5 December 2017

15 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14601096

full work available at URL

29 March 2024

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.11775

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14601096

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.11775

29 March 2024

1 reference

https://api.crossref.org/works/10.1002/CNCR.11775

https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.11775

29 March 2024

1 reference

https://api.crossref.org/works/10.1002/CNCR.11775

29 March 2024

1 reference

5 December 2017

98

1 reference

5 December 2017

2251-2256

1 reference

5 December 2017

10

1 reference

Malignant vascular tumors in children and adolescents: A report from the Italian and German soft tissue sarcoma cooperative group

5 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Prognostic factors and survival in late adolescent and adult patients with small round cell tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

The mechanisms of action of PPARs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Differentiation and reversal of malignant changes in colon cancer through PPARgamma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Terminal differentiation of human breast cancer through PPAR gamma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

The contributions of cyclooxygenase-2 to tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

A case of angiosarcoma of the face successfully treated with combined chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Angiosarcoma of skin and soft tissue: a study of forty-four cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11775

7 January 2021

Identifiers

DOI

10.1002/CNCR.11775

1 reference

5 December 2017

1 reference